Reuters: Germany’s Merck KGaA in $3.9 billion deal to buy US biotech firm SpringWorks

Equity research firm MKP Advisors was among those who speculated rival bidders might emerge.

“The market might hope that the offer price, lower than originally envisaged, entices others to have a look,” MKP Managing Director Thomas Nienaber said in a report.